- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04855630
Combating Alzheimer's Through Sleep and Exercise (CASE)
Combating Alzheimer's Through Sleep and Exercise (CASE)
The Combating Alzheimer's through Sleep and Exercise (CASE) study is an exploratory, hypothesis-generating trial designed to: (1) assess whether improvements in sleep are associated with improvements in cognitive performance and cardiovascular and metabolic health; (2) evaluate the effects of structured, moderate-level aerobic and anaerobic exercise on cognitive performance and cardiovascular and metabolic health; (3) examine the combined, potentially synergistic effects of both interventions on cognitive performance and cardiovascular and metabolic health; and (4) investigate the role of light exposure as a potential modulator of sleep parameters.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Azizi A Seixas, PhD
- Phone Number: 3052431301
- Email: Azizi.seixas@med.miami.edu
Study Contact Backup
- Name: Debbie Chung, PhD
- Phone Number: 3052431301
- Email: dxc1729@miami.edu
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33136
- Recruiting
- University of Miami Hospitals
-
Contact:
- Azizi A Seixas, PhD
- Phone Number: 3052431301
- Email: Azizi.seixas@med.miami.edu
-
Principal Investigator:
- Azizi A Seixas, PhD
-
Sub-Investigator:
- Alberto Ramos, MD
-
Contact:
- Debbie Chung, PhD
- Phone Number: 3052431301
- Email: dxc1729@miami.edu
-
Sub-Investigator:
- Debbie Chung, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged 55-80 years at the time of the screening visit
- Able to ambulate safely and independently
- Able to safely perform moderate-intensity exercise as per the Physical Activity Readiness Questionnaire (PAR-Q, a validated exercise readiness questionnaire)
- Able to wear and use Fitbit wristwatch and/or the Elemind Neuromodulation headband and Lys devices
- Able to operate a digital device like mobile phone or computer
- Able and willing to provide venous blood samples
- Able to understand and speak English (our AR-based MCI diagnosis tool does not yet have capacity for other languages)
- Able to self-report a history of cognitive changes or impairment
- Be cognitively able (including those with and without MCI) and willing to provide informed consent
- Body weight <400 pounds (<181.4kg) in order to safely operate the NuStep T4r Recumbent Stepper stationary bicycle
Exclusion Criteria:
- Severe mobility limitations that prevent safe participation in moderate exercise protocols
- Unstable or uncontrolled medical conditions (e.g., recent cardiovascular event (<6 months), cerebrovascular accident or transient ischemic attack (<6 months), active cancer, or uncontrolled diabetes) that pose safety concerns
- Inability to complete intake screening procedures
- Severe uncorrected hearing impairment-particularly if it precludes effective utilization of the Elemind Neuromodulation headband-and/or vision impairment that interferes with digital device usage or in-person exercise guidance
- Determined to have Alzheimer's/dementia based on performance on the Quick Mild Cognitive Impairment (QMCI).
- Inability or unwillingness to learn or engage with digital devices (e.g., smartphone, Fitbit, Elemind, or Lys), even with staff support
- Regular pre-study engagement in ≥150 minutes of moderate-level and/or ≥75 minutes of vigorous-level exercise per week based on Fitbit data obtained during the initial seven-day onboarding screening period
- Determined to have sufficient sleep, as defined by a sleep efficiency mean of ≥80%) based on Elemind Neuromodulation headband data obtained during the initial seven-day onboarding screening period
- Current usage of disease-modifying therapy targeting amyloid (e.g., anti-amyloid monoclonal antibodies) or tau
- Body weight ≥400 pounds (≥181.4kg), which would pose a safety risk during the operation of the NuStep recumbent stationary bicycle
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Sleep Only Group
Participants in this group will wear the Elemind headband 3-4 times weekly for 8 weeks. |
The Elemind Neuromodulation headband is a wearable device that utilizes noninvasive, electroencephalography-based (EEG-based) technology to induce a sleep state more rapidly via personalized acoustic stimulation. Specifically, the headband uses a closed-loop system, meaning that the headband conveys stimulation based upon recorded neural activity in order to modulate real-time oscillating circuits at the macroscopic level. This device uses five dry, flexible EEG electrodes-including three recording electrodes that are positioned at the Fpz and Fp1/2 electrode sites in accordance with the 10-20 International System of electrode placement and two silicone rubber-based, linked reference electrodes located at the mastoids-to measure neural activity during sleep and provide an estimation of the phases of real-time neural oscillations. The headband generates a sound pulse by identifying alpha neural oscillations in real-time through endpoint-corrected Hilbert Transform algorithm. |
|
Active Comparator: Exercise Only Group
Participants in this group will participate in a structured, on-site, twice a week exercise program for 60 minutes/session for 8 weeks (16 total sessions). Each exercise session is comprised of 60 minutes, including 10 minutes of warm-up, 20 minutes of cardiovascular exercise on a stationary bike, 20 minutes of resistance training (1 day of upper body focus, 1 day of lower body focus each week), and 10 minutes of cooling off). |
Participants randomized to the exercise-only group will engage in an 8-week, home- and site-based exercise intervention designed for older adults across a range of cognitive and physical function levels. All site-based sessions will occur in-person at the study facility under supervision of trained staff. Each week, participants will attend two 60-minute structured exercise sessions, consisting of aerobic training and resistance training. On the remaining five days when subjects will not engage in structured exercise, subjects will be asked to engage in 30 minutes of moderate-intensity walking activities. In-lab exercise protocols will be fully standardized to ensure consistency of exercise dosage and fidelity across participants. The target exercise load will be 270 minutes of moderate-intensity exercise weekly for 8 weeks. |
|
Active Comparator: Exercise and Sleep Group
Participants in this group will take part in the on-site, structured exercise program twice per week for 8 weeks in additional to wearing the Elemind headband 3-4 times per week for 8 weeks. |
The Elemind Neuromodulation headband is a wearable device that utilizes noninvasive, electroencephalography-based (EEG-based) technology to induce a sleep state more rapidly via personalized acoustic stimulation. Specifically, the headband uses a closed-loop system, meaning that the headband conveys stimulation based upon recorded neural activity in order to modulate real-time oscillating circuits at the macroscopic level. This device uses five dry, flexible EEG electrodes-including three recording electrodes that are positioned at the Fpz and Fp1/2 electrode sites in accordance with the 10-20 International System of electrode placement and two silicone rubber-based, linked reference electrodes located at the mastoids-to measure neural activity during sleep and provide an estimation of the phases of real-time neural oscillations. The headband generates a sound pulse by identifying alpha neural oscillations in real-time through endpoint-corrected Hilbert Transform algorithm. Participants randomized to the exercise-only group will engage in an 8-week, home- and site-based exercise intervention designed for older adults across a range of cognitive and physical function levels. All site-based sessions will occur in-person at the study facility under supervision of trained staff. Each week, participants will attend two 60-minute structured exercise sessions, consisting of aerobic training and resistance training. On the remaining five days when subjects will not engage in structured exercise, subjects will be asked to engage in 30 minutes of moderate-intensity walking activities. In-lab exercise protocols will be fully standardized to ensure consistency of exercise dosage and fidelity across participants. The target exercise load will be 270 minutes of moderate-intensity exercise weekly for 8 weeks. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Glycated Hemoglobin (HbA1c) Levels
Time Frame: Up to Week 8
|
Measured from blood sample |
Up to Week 8
|
|
Total Cholesterol Levels
Time Frame: Up to Week 8
|
Measured from blood sample |
Up to Week 8
|
|
Triglycerides Levels
Time Frame: Up to Week 8
|
Measured from blood sample |
Up to Week 8
|
|
High-sensitivity C-reactive protein (hs-CRP) Levels
Time Frame: Up to Week 8
|
Measured from blood sample |
Up to Week 8
|
|
Low-Density Lipoprotein (LDL) Levels
Time Frame: Up to Week 8
|
Measured from blood sample |
Up to Week 8
|
|
C-Peptides
Time Frame: Up to Week 8
|
Measured from blood sample |
Up to Week 8
|
|
High-Density Lipoprotein (HDL) Levels
Time Frame: Up to Week 8
|
Measured from blood sample |
Up to Week 8
|
|
Cognitive Function
Time Frame: Up to 8 weeks
|
Cognitive function gauged from Altoida's Digital Neuro-Signatures |
Up to 8 weeks
|
|
Insulin Levels
Time Frame: Up to 8 weeks
|
Measured from blood sample |
Up to 8 weeks
|
|
Neurofilament light chain
Time Frame: Up to Week 8
|
Measured from blood sample |
Up to Week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total Sleep Duration
Time Frame: Up to Week 8
|
Measured from Elemind |
Up to Week 8
|
|
Slow Wave Sleep Duration
Time Frame: Up to Week 8
|
Measured from Elemind |
Up to Week 8
|
|
%Slow-wave Sleep
Time Frame: Up to Week 8
|
Measured by Elemind headband |
Up to Week 8
|
|
Rapid Eye Movement Duration
Time Frame: Up to Week 8
|
Measured by Elemind headband |
Up to Week 8
|
|
%REM
Time Frame: Up to Week 8
|
Measured by Elemind headband |
Up to Week 8
|
|
Light Non-Rapid Eye Movement Duration
Time Frame: Up to Week 8
|
Measured by Elemind headband |
Up to Week 8
|
|
%Light Non-Rapid Eye Movement Sleep
Time Frame: Up to Week 8
|
Measured by Elemind headband |
Up to Week 8
|
|
Sleep Efficiency
Time Frame: Up to Week 8
|
Measured by Elemind headband |
Up to Week 8
|
|
Sleep Onset Latency
Time Frame: Up to Week 8
|
Measured by Elemind headband |
Up to Week 8
|
|
Restlessness (Restless Bouts/Hour during Sleep)
Time Frame: Up to Week 8
|
Measured by Elemind headband |
Up to Week 8
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Light Exposure
Time Frame: Up to Week 8
|
Measured by LYS Device |
Up to Week 8
|
|
Psychosocial Metrics
Time Frame: Up to Week 8
|
Measured by Questionnaires |
Up to Week 8
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Azizi A Seixas, PhD, University of Miami
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20220931
- 20-01023 (Other Identifier: NYU)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.